Acute Brain Injury in New-Onset Refractory Status Epilepticus and Etiology-Defined Status Epilepticus
Authors:
- 1 June 2026
- journal article
- Published by American Medical Association (AMA) in JAMA Neurology
- Vol. 83 (6) , 563
Abstract
Importance: Seizure-induced brain injury is central to the treatment urgency of new-onset refractory status epilepticus (NORSE). Identifying biomarkers that reflect ongoing neuronal damage could inform therapeutic timing and improve outcomes. Objective: To quantify acute brain injury in patients with cryptogenic NORSE (cNORSE), etiology-defined status epilepticus (eSE), and chronic epilepsy. Design, Setting, and Participants: This was an international cross-sectional study conducted between 2013 and 2025. Patients were enrolled at 36 hospitals in the US, 2 in Canada, and 1 in Italy, France, and Belgium. Patients with cNORSE and eSE for which biological samples were obtained during ongoing seizure activity were enrolled in the study. Comparison groups without status epilepticus comprised individuals with chronic epilepsy and healthy participants. None were excluded. Exposures: Neurofilament light chain (NfL) and S100-beta (S100B) protein concentrations in serum and cerebrospinal fluid (CSF). Main Outcomes and Measures: Degree of neuronal and glial damage, indexed by NfL and S100B levels, and their association with short-term functional outcomes. Results: A total of 78 patients with cNORSE (mean [95% CI] age, 37 [30-41] years; 44 female [56%]) and 2 independent cohorts of 211 patients (mean [95% CI] age, 69 [66-71] years; 128 female [61%]) and 73 patients (mean [95% CI] age, 56 [45-65] years; 39 male [53%]) with eSE were included. NfL concentrations were markedly elevated in cNORSE—approximately 10-fold higher in CSF and 4-fold higher in serum—compared with the eSE cohorts (CSF: median [IQR], 6408 [1503-22 963] pg/mL compared with 694 [219-2389] pg/mL; serum: median [IQR], 231 [99-855] pg/mL compared with 55 [20-135] pg/mL; P <.001). Serum NfL levels were nearly 20-fold higher in cNORSE than in the cohort with epilepsy and in healthy controls (median [IQR], 11 [7-19 ] and 7 [5-14 ] pg/mL, respectively). Serum and CSF NfL levels were strongly correlated (Spearman ρ = 0.75; P < .001) and rose sharply between week 1 (median [IQR], 101 [51-137] pg/mL), week 2 (median [IQR], 197 [117-324] pg/mL), and week 3 (median [IQR], 598 [163-1000] pg/mL) after onset ( P < .001). In contrast, S100B concentrations did not differ between groups and showed no consistent temporal pattern. NfL discriminated cNORSE from eSE (area under the receiver operating characteristic curve [AUROC], 0.79; 95% CI, 0.68-0.90) and from cohorts without status epilepticus (AUROC, 0.99; 95% CI, 0.78-1.00). Higher serum NfL was independently associated with poor functional outcome at discharge (Glasgow Outcome Scale extended score, 1-4; odds ratio, 1.01; 95% CI, 1.00-1.03; P = .03). Conclusions and Relevance: Results of this cross-sectional study suggest that acute neuroaxonal injury, as reflected by elevated NfL levels, was substantially greater in cNORSE than in the cohorts with eSE and in controls without status epilepticus. The rapid early rise in NfL highlights a narrow therapeutic window, emphasizing the need for prompt, effective, and potentially neuroprotective interventions in cNORSE.Keywords
This publication has 40 references indexed in Scilit:
- Comparative analysis of new-onset refractory status epilepticus in adult and pediatric patients: immunotherapy timing and functional outcomesJournal of Neurology, 2025
- CSF Tau Is a Biomarker of Hippocampal Injury in Cryptogenic New‐Onset Refractory Status EpilepticusAnnals of Clinical and Translational Neurology, 2025
- Cytokines inNew‐OnsetRefractory Status Epilepticus Predict OutcomesAnnals of Neurology, 2023
- Neurofilament light (NfL) as biomarker in serum and CSF in status epilepticusJournal of Neurology, 2023
- Neuron Specific Enolase, S100-beta protein and progranulin as diagnostic biomarkers of status epilepticusJournal of Neurology, 2022
- Brain pathology in focal status epilepticus: evidence from experimental modelsNeuroscience & Biobehavioral Reviews, 2021
- Change in Mortality of Generalized Convulsive Status Epilepticus in High-Income Countries Over TimeJAMA Neurology, 2019
- Progressive Brain Atrophy in Super-refractory Status EpilepticusJAMA Neurology, 2016
- Cerebrospinal fluid tau proteins in status epilepticusEpilepsy & Behavior, 2015
- Prolonged Epileptic Seizures in PrimatesArchives of Neurology, 1973